Eleni Bouronikou
Larisa, ESYE14, Greece
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients.
Journal: British journal of haematology
Published: January 17, 2025
Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries.
Journal: Leukemia
Published: September 04, 2022
Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.
Journal: Blood cancer journal
Published: September 24, 2020
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.
Journal: Therapeutic advances in hematology
Published: July 08, 2020
Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort study.
Journal: EJHaem
Published: May 12, 2020
Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Journal: Journal of geriatric oncology
Published: March 28, 2019
The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Journal: Hematological oncology
Published: August 03, 2018
Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group.
Journal: Leukemia research
Published: May 31, 2018
The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
Journal: American journal of hematology
Published: March 29, 2018
A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece.
Journal: International journal of hematology
Published: March 21, 2016
A primary hepatic lymphoma treated with liver resection and chemotherapy.
Journal: Case reports in surgery
Published: May 04, 2014
Metabolism-related cytokine and hormone levels in the serum of patients with myelodysplastic syndromes.
Journal: Acta haematologica
Published: January 26, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026